Drägerwerk AG & Co. KGaA (ETR:DRW3) Trading 0.6% Higher - Time to Buy?

Key Points

• Drägerwerk AG & Co. KGaA shares rose by 0.6% during mid-day trading, reaching €65.70 ($76.40), while trading volume dipped significantly by 67% compared to the average session.
• The company has a market capitalization of $1.15 billion and solid financial metrics, including a P/E ratio of 10.87 and a current ratio of 1.89.
• Drägerwerk AG operates in the medical and safety technology sectors, providing solutions and services for healthcare and industrial safety markets.

Shares of Drägerwerk AG & Co. KGaA (ETR:DRW3 - ) traded up 0.6% during mid-day trading on Monday . The company traded as high as €65.90 ($76.63) and last traded at €65.70 ($76.40). 11,163 shares traded hands during mid-day trading, a decline of 67% from the average session volume of 33,804 shares. The stock had previously closed at €65.30 ($75.93).

Drägerwerk AG & Co. KGaA Trading Up 0.6%

The stock has a market capitalization of $1.15 billion, a P/E ratio of 10.87, a PEG ratio of 1.24 and a beta of -0.31. The company has a debt-to-equity ratio of 20.57, a current ratio of 1.89 and a quick ratio of 0.81. The business's 50 day simple moving average is €66.57 and its 200-day simple moving average is €65.77.

About Drägerwerk AG & Co. KGaA

Drägerwerk AG & Co KGaA operates as a medical and safety technology company worldwide. It develops, produces, and markets system solutions, equipment, and services for acute point of care, including emergency medicine, perioperative care, intensive care, and perinatal medicine. The company also develops, produces, and markets products, system solutions, and services for personal protection, gas detection technology, and integrated hazard management to customers in industry and mining sectors, as well as public sectors, such as fire departments, police, and disaster protection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.